Dr Fiona Kennedy will investigate the feasibility of an online resource to offer support to secondary breast cancer patients and help them to manage their symptoms with the ultimate aim of improving their overall quality of life.

Dr Anna Git will be studying the role of molecules called mid-sized non-coding RNAs, which she believes could have a more important role in breast cancer than previously thought. Her work will lead to a better understanding of breast cancer, and hopefully improved treatments.

Using the immune system to target tumours has been hailed as one of the next great breakthroughs in treating cancers, with the potential to use the patient’s own immune cells to specifically recognise and attack cancer cells. However, there is still much to learn if we are to use these immunotherapies to safely and effectively treat breast cancer whilst avoiding damage to healthy tissues.

The drugs crizotinib and lorlatinib have the potential to be new treatments for various forms of breast cancer. Professor Lord and his team will be investigating how these drugs work and using that information to work out the best way to use them to benefit patients.

Professor Nicholas Turner and Dr Alicia Okines will lead a clinical trial of the drug crizotinib for patients with lobular breast cancer that has spread to other parts of the body. This trial, called the ROLO study, could lead to a much-needed new treatment for this type of breast cancer.

Dr Boyne will investigate whether the increased risk of secondary breast cancer in patients with type-two diabetes is caused by ‘molecular messages’ carried in fragments of blood cells known as platelets.